Opendata, web and dolomites

NeuroProtect

Novel Drug Therapy with Potential to Cure Neuro-Degenerative Diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NeuroProtect project word cloud

Explore the words cloud of the NeuroProtect project. It provides you a very rough idea of what is the project "NeuroProtect" about.

perform    apoptotic    amyotrophic    300m    proven    clinical    positions    diseases    over    parkinson    anti    route    industry    efficiency    mouse    patient    led    showed    outgrowth    phase    founders    guan    neurons    burden    succeed    extensive    update    significance    planning    approval    neurodegenerative    companies    pd    natural    refund    lifetime    neuro    finish    orphan    japan    multinational    tests    commercialization    whilst    global    disease    outlicense    team    faster    fastest    honeywell    europeans    worked    pharma    plan    pay    ad    switzerland    therapies    physician    total    remarkable    dong    10m    preliminary    socioeconomic    investors    gives    until    rare    pharmaceutical    suffer    royalties    ip    reduce    lateral    models    strategy    herb    standard    dr    healing    trials    cure    select    alone    neuroprotective    neuronal    damaged    als    drug    co    compound    game    reverse    david    changer    alzheimer    business    rescuing    treat    sclerosis    drugs    primary    symptoms    company    vitro    human    market    axon    economic    advisors    neuroprotect    15m    yuhong    hp    relatively   

Project "NeuroProtect" data sheet

The following table provides information about the project.

Coordinator
SUNREGEN HEALTHCARE AG 

Organization address
address: ROBINIENWEG 51
city: Reinach
postcode: 4153
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website http://www.sunregen.ch
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-06-01   to  2018-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SUNREGEN HEALTHCARE AG CH (Reinach) coordinator 50˙000.00

Map

 Project objective

Over 10M Europeans suffer from neurodegenerative diseases such as Alzheimer’s Disease (AD), Parkinson’s Disease (PD) and Amyotrophic Lateral Sclerosis (ALS). Whilst there are many drugs that treat symptoms of these diseases, there are no therapies that can reverse or cure them. Our novel compound NeuroProtect has the potential to be a game changer by healing damaged neurons. NeuroProtect is a natural herb-derived compound with remarkable neuroprotective, neuro-rescuing, anti-apoptotic, and axon-outgrowth effects in mouse primary neuronal and human neuronal models. We have proven the compound’s efficiency in preliminary in-vitro tests. To take NeuroProtect to market fastest, we will focus on ALS that where we can use the orphan drug route and get clinical approval faster. This gives us an immediate target market of €300M per year in Europe, the US, Japan and Switzerland alone. Although ALS is relatively rare, the socioeconomic significance of the disease is extensive: a recent study showed that total lifetime costs for ALS were €1.15M per patient. NeuroProtect can therefore contribute to reduce the global economic burden of ALS. We are planning to take the standard route for commercialization in pharma industry: take the compound through pre-clinical studies, Phase I and Phase II clinical trials and then outlicense to a large pharma company who will refund our cost until they finish the Phase III trials and then pay us royalties. Our team is led by two experienced co-founders: Dr. Yuhong Dong, who has worked for a multinational pharmaceutical company for over 10 years as well as a physician for 4 years, and David Guan, who has over 10 years of management positions at multinational companies (HP, Honeywell). We are also supported by experienced advisors and investors to help us succeed. We are planning to use the Phase 1 funding to select our pre-clinical study partners, perform a market assessment, assess our IP strategy and update our business plan.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEUROPROTECT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEUROPROTECT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

PrasinoMed (2018)

First in the world ecological and sustainable cream for wound care, based on microalgaprasinococcus capsulatus

Read More  

PME Instrument v2 (2018)

Second generation chatbot development platform

Read More  

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More